Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

250
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
250
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

603
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
603
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.9K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and demographic profile of pediatric cataracts among Omani children presenting to a tertiary eye care center, Oman.

Oman journal of ophthalmology·2023
Same author

Subluxated cataractous lens and high myopia: An uncommon association in an achondroplasia child.

Oman journal of ophthalmology·2023
Same author

A multicenter double-blind, placebo-controlled randomized trial to evaluate the safety and efficacy of bovine colostrum in the treatment of severe alcoholic hepatitis (SAH).

Trials·2023
Same author

Celiac disease and intussusception - a rare but important association.

Acta gastro-enterologica Belgica·2022
Same author

Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease.

The Journal of the Association of Physicians of India·2020
Same author

Primary angle-closure glaucoma: A retrospective interventional case series in South India.

Oman journal of ophthalmology·2016

Related Experiment Video

Updated: Feb 13, 2026

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

36.4K

Sorafenib induced hepatic encephalopathy.

S S Sidhu1, S Agarwal1, O Goyal1

  • 1Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

Acta Gastro-Enterologica Belgica
|March 22, 2018
PubMed
Summary

Sorafenib, a medication used to prevent liver cancer recurrence, can cause hepatic encephalopathy. This condition involves high ammonia levels and neurological symptoms, which resolved upon drug withdrawal.

Area of Science:

  • Hepatology
  • Oncology
  • Neurology

Background:

  • Hepatocellular carcinoma (HCC) is a common complication of Hepatitis C related cirrhosis.
Keywords:
Sorafenibhepatic encephalopathyhepatocellular carcinoma

More Related Videos

A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila
10:15

A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila

Published on: July 4, 2017

8.7K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.9K

Related Experiment Videos

Last Updated: Feb 13, 2026

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

36.4K
A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila
10:15

A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila

Published on: July 4, 2017

8.7K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.9K
  • Surgical resection and adjuvant therapies like Sorafenib are used to prevent HCC recurrence.
  • Hepatic encephalopathy (HE) is a serious complication of liver disease.